On August 31, 2022 Bristol Myers Squibb (NYSE: BMY) reported that the company will take part in a fireside chat at Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022 in Boston, Massachusetts (Press release, Bristol-Myers Squibb, AUG 31, 2022, View Source [SID1234618821]). Company executives will answer questions about the company at 8:50 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session at View Source An archived edition of the session will be available later that day.

On August 31, 2022 NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, reported that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to take place in-person in New York and virtually September 12th-14th 2022 (Press release, Nanobiotix, AUG 31, 2022, View Source [SID1234618838]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the events page of the Investors section of the Company’s website. A replay will be available on the Nanobiotix website within 48 hours of the event. The Company’s corporate presentation can be downloaded here.

On August 31, 2022 Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September (Press release, Decibel Therapeutics, AUG 31, 2022, View Source [SID1234618805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 17th Annual BioPharma Conference:

Rare disease panel on Wednesday, September 7, 2022 at 11:20 a.m. ET in Boston, MA.
H.C. Wainwright 24th Annual Global Investment Conference:

Virtual presentation available for on demand viewing starting on Monday, September 12, 2022 at 7:00 a.m. ET
Baird 2022 Global Healthcare Conference:

Fireside chat on Tuesday, September 13, 2022 at 3:10 p.m. ET in New York, NY.
Cantor Cell & Genetic Medicines Conference:

Panel titled, "Ring Ring: Is That Large-Cap Pharma Calling? Importance of Established Partnerships in Place," on Thursday, September 15, 2022 at 8:00 a.m. ET in New York, NY.
Webcasts of the Citi, H.C. Wainwright and Baird events may be accessed by visiting the Investors section of the Decibel Therapeutics website at View Source An archived replay of the webcasts will be available on the Company’s website for approximately 90 days following these events.

On August 31, 2022 Veracyte, Inc. (Nasdaq: VCYT) reported that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022, taking place September 9-13, 2022, in Paris (Press release, Veracyte, AUG 31, 2022, View Source [SID1234618822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The abstracts we’ll share at ESMO (Free ESMO Whitepaper) 2022 reinforce the value our genomic tests bring to physicians diagnosing and treating cancer patients," said Marc Stapley, Veracyte’s chief executive officer. "We are particularly excited about new data from a post-hoc analysis that evaluated the clinical performance of our Decipher Prostate test in one arm of the large, multi-center, randomized STAMPEDE trial. We believe these data may help expand the Decipher test’s availability to advanced prostate cancer patients in the United States, and also support our plans to offer the Decipher Prostate test as an IVD on the nCounter Analysis System for use outside of the United States where laboratories can perform it locally."

Following are details of the abstracts that will be shared as part of the ESMO (Free ESMO Whitepaper) 2022 Congress:

On August 31, 2022 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Citigroup 17th Annual Biopharma Conference on Wednesday, September 7, 2022 at 6:40 a.m. PDT / 9:40 a.m. EDT (Press release, Atara Biotherapeutics, AUG 31, 2022, View Source [SID1234618839]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investor Events and Presentations section of atarabio.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the live presentation.